Mantle Cell Lymphoma Clinical Trials in New York, New York

7 recruitingNew York, New York

Showing 17 of 7 trials

Recruiting
Phase 1Phase 2

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+6 more
BeOne Medicines614 enrolled127 locationsNCT05006716
Recruiting
Phase 3

A Long-term Extension Study of PCI-32765 (Ibrutinib)

Chronic Lymphocytic LeukemiaMantle Cell LymphomaFollicular Lymphoma+1 more
Janssen Research & Development, LLC700 enrolled174 locationsNCT01804686
Recruiting
Phase 3

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

Mantle Cell Lymphoma
Alliance for Clinical Trials in Oncology421 enrolled233 locationsNCT05976763
Recruiting
Phase 1

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)Waldenstrom Macroglobulinemia (WM)+2 more
Nurix Therapeutics, Inc.248 enrolled16 locationsNCT04830137
Recruiting
Phase 1

A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma

Mantle Cell LymphomaMCL
Memorial Sloan Kettering Cancer Center39 enrolled10 locationsNCT06192888
Recruiting
Phase 2

BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma

LymphomaMantle Cell Lymphoma
Christine Ryan60 enrolled7 locationsNCT06854003
Recruiting
Phase 2

Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma

Mantle Cell Lymphoma
Academic and Community Cancer Research United45 enrolled7 locationsNCT04626791